$0.7447
-0.0153[-2.01%]
At close: Apr 24
$0.7447
0[0.00%]
PreMarket: 6:24AM EDT
Seres Therapeutics
(NASDAQ:MCRB)Seres Therapeutics Stock (NASDAQ:MCRB), Analyst Ratings, Price Targets, Predictions
Seres Therapeutics Inc has a consensus price target of $10.28, established from looking at the 20 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Chardan Capital, and Oppenheimer on March 6, 2024, March 6, 2024, and January 16, 2024. With an average price target of $7.33 between Oppenheimer, Chardan Capital, and Oppenheimer, there's an implied 884.74% upside for Seres Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Chardan Capital
Goldman Sachs
Oppenheimer
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Seres Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/06/2024 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 571.41% | Oppenheimer | Jeff Jones | $9 → $5 | Maintains | Outperform | Get Alert |
| 03/06/2024 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 974.26% | Chardan Capital | Keay Nakae | $10 → $8 | Maintains | Buy | Get Alert |
| 01/16/2024 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 1108.54% | Oppenheimer | Jeff Jones | $10 → $9 | Maintains | Outperform | Get Alert |
| 11/03/2023 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 67.85% | Goldman Sachs | Chris Shibutani | $4 → $1.25 | Maintains | Sell | Get Alert |
| 06/26/2023 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 1511.39% | Oppenheimer | Mark Breidenbach | → $12 | Assumes | → Outperform | Get Alert |
| 04/28/2023 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 1242.82% | Chardan Capital | Keay Nakae | $12 → $10 | Maintains | Buy | Get Alert |
| 04/21/2023 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 839.98% | JP Morgan | Tessa Romero | → $7 | Initiates | → Neutral | Get Alert |
| 03/21/2023 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 1914.23% | Canaccord Genuity | John Newman | $11 → $15 | Maintains | Buy | Get Alert |
| 03/08/2023 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 1377.1% | Canaccord Genuity | John Newman | $17 → $11 | Maintains | Buy | Get Alert |
| 03/08/2023 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 1511.39% | Chardan Capital | Keay Nakae | → $12 | Reiterates | → Buy | Get Alert |
| 03/08/2023 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 3257.06% | HC Wainwright & Co. | Vernon Bernardino | → $25 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 3257.06% | HC Wainwright & Co. | Vernon Bernardino | → $25 | Reiterates | → Buy | Get Alert |
| 09/07/2022 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 1108.54% | Piper Sandler | Edward Tenthoff | $7 → $9 | Maintains | Overweight | Get Alert |
| 05/23/2022 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 839.98% | Piper Sandler | Edward Tenthoff | $32 → $7 | Maintains | Overweight | Get Alert |
| 07/23/2021 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 3794.19% | Canaccord Genuity | John Newman | — | Maintains | Buy | Get Alert |
| 07/23/2021 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 2048.52% | Chardan Capital | Keay Nakae | — | Maintains | Buy | Get Alert |
| 07/23/2021 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 2317.08% | Oppenheimer | Mark Breidenbach | — | Maintains | Outperform | Get Alert |
| 07/23/2021 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 3257.06% | HC Wainwright & Co. | Vernon Bernardino | — | Maintains | Buy | Get Alert |
| 07/23/2021 | MCRB | Buy Now | Seres Therapeutics | $0.74 | 839.98% | Goldman Sachs | Chris Shibutani | — | Downgrade | Neutral → Sell | Get Alert |
FAQ
What is the target price for Seres Therapeutics (MCRB)?
The latest price target for Seres Therapeutics (NASDAQ: MCRB) was reported by Oppenheimer on March 6, 2024. The analyst firm set a price target for $5.00 expecting MCRB to rise to within 12 months (a possible 571.41% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Seres Therapeutics (MCRB)?
The latest analyst rating for Seres Therapeutics (NASDAQ: MCRB) was provided by Oppenheimer, and Seres Therapeutics maintained their outperform rating.
When was the last upgrade for Seres Therapeutics (MCRB)?
There is no last upgrade for Seres Therapeutics.
When was the last downgrade for Seres Therapeutics (MCRB)?
The last downgrade for Seres Therapeutics Inc happened on July 23, 2021 when Goldman Sachs changed their price target from $24 to $7 for Seres Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Seres Therapeutics (MCRB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seres Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seres Therapeutics was filed on March 6, 2024 so you should expect the next rating to be made available sometime around March 6, 2025.
Is the Analyst Rating Seres Therapeutics (MCRB) correct?
While ratings are subjective and will change, the latest Seres Therapeutics (MCRB) rating was a maintained with a price target of $9.00 to $5.00. The current price Seres Therapeutics (MCRB) is trading at is $0.74, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.